Efficacy of Ultrasound-guided Injection of 5% Dextrose for Meralgia Paresthesia

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

40 participants

Study Classification

INTERVENTIONAL

Study Start Date

2022-01-01

Study Completion Date

2024-01-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Meralgia paresthetica (MP) is one of the most common peripheral entrapment neuropathies of the lower limbs. It is characterized by paresthesia, pain, tingling, numbness, hypersensitivity, or other abnormal skin sensations on the anterolateral aspect of the thigh. The condition results from compression of the lateral femoral cutaneous nerve (LFCN) along its course, often occurring as the nerve exits the pelvis.The injection of 5% dextrose (D5W) under ultrasound guidance is a novel treatment method for peripheral nerve entrapment. However, there is limited evidence about the efficacy of this method for patients with MP. The investigators found D5W was more safe and effective than corticosteroids for patients with MP. Thus, this study aimed to evaluate the 6-month efficacy of ultrasound-guided injection of D5W for MP patients.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Efficacy of Neural Prolotherapy in Treatment of Meralgia Paresthetica

NCT04499911

Meralgia Paresthetica

COMPLETED NA

Dorsal Scapular Nerve Injection Combined With Muscle Needle Release

NCT06329960

Dorsal Scapular Nerve Entrapment

NOT_YET_RECRUITING NA

Effect of Different Ultrasound Doses on Median Nerve Conduction Parameters

NCT05233488

Entrapment Neuropathies

UNKNOWN NA

High Tone Power Therapy Versus Transcutanuoselectrical Nerve Stimulation on Polyneuropathic Pain in Diabetic Patients

NCT06822218

Diabete Mellitus

RECRUITING NA

Effect of High Tone Power Therapy on Neurophysiological Measures and Function Outcome in Patients With Diabetic Neuropathy

NCT03888872

Diabetic Neuropathy Peripheral

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Meralgia Paresthetica

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

D5W group

The patients received one session of ultrasound-guided 10ml D5W injection around the lateral femoral cutaneous nerve as it exited the pelvis.

Group Type EXPERIMENTAL

injection

Intervention Type OTHER

10ml D5W injection for MP patients

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

injection

10ml D5W injection for MP patients

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* patients aged between 18 and 80 years;
* those diagnosed with MP based on clinical and physical examination, with symptoms persisting for at least 3 months;
* a high-resolution ultrasound revealing LFCN compression as it exited the pelvis.

Exclusion Criteria

* MP resulting from trauma, surgery or occupying lesions affecting the LFCN;
* pregnancy;
* concurrent presence of rheumatic immune diseases, hypothyroidism, or diabetes mellitus;
* a known history of allergy to lidocaine or corticosteroids;
* L2/3 lumbar radiculopathy;
* patients who had undergone local injection or surgery for MP within 3 months

Minimum Eligible Age

18 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No